Creating detection devices that increase productivity and save lives. Based in Boulder, CO the company integrates innovative technologies in various device platforms through strategic partnerships, licensing agreements and acquisitions. Currently we are pilot testing with international employers our first patented and proprietary device SOBRCheck, a non-invasive, touch-based identity verification and alcohol detection solution.
Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, and listed on the Toronto Stock Exchange (TMD) and on NASDAQ in the United States (TMDI). Titan is focused on the design, development and commercialization of novel advanced robotic surgical technologies such as SPORT(TM) Surgical System. Titan`s SPORT Surgical System is a versatile single incision advanced robotic platform that features state-of the-art multi-articulated instruments with unique replaceable tips, 3D visualization on High Definition flat-screen monitor, highly ergonomic open workstation with natural surgeon interface and a single low-profile patient cart for ease of set up that enables broad applications of single and multi-quadrant surgeries. The SPORT Surgical System`s smart design elements are geared with the specific goals of delivering superior clinical capabilities and unparalleled OR efficiency at the operating costs similar to Laparoscopic Surgery in mind. Titan Medical Inc. is focused on delivering the promise of Robotic Surgery Optimized. SPORT Surgical System is currently not cleared by FDA or doesn`t have the CE mark.
Med Services is a Bohemia, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LiveData is a leading innovator of real-time data integration and display technology.
MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, accurate single-use device. MY01. The simple solution to a dangerous problem.